Intuitive Surgical (NSDQ:ISRG) shares recouped some recent losses today after the medical device company announced 510(k) clearance from the FDA for its da Vinci Sp single-site robot-assisted surgery platform in urological procedures.
It’s the 2nd FDA nod for Intuitive this month, following the April 1 clearance of its da Vinci Xi platform.
Today’s news sent ISRG shares ticking up 1.4% to $416.70 apiece as of about 11 a.m. The stock had declined steadily from the $541.23 high reached after the da Vinci Xi approval, sliding 12.7% to a $411.11 close yesterday.
Investors’ ardor for the single-site Sp device today is likely tempered by the fact that Intuitive doesn’t expect the platform to hit the market until 2nd half of 2015, once it’s been cleared as compatible with the Xi platform.
"Our development of this single-port technology represents our foundational commitment to advancing tools for minimally invasive surgery," president & CEO Gary Guthart said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.